DE69732535D1 - Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression - Google Patents

Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression

Info

Publication number
DE69732535D1
DE69732535D1 DE69732535T DE69732535T DE69732535D1 DE 69732535 D1 DE69732535 D1 DE 69732535D1 DE 69732535 T DE69732535 T DE 69732535T DE 69732535 T DE69732535 T DE 69732535T DE 69732535 D1 DE69732535 D1 DE 69732535D1
Authority
DE
Germany
Prior art keywords
protein
regulating
expression
oligonucleotide composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69732535T
Other languages
English (en)
Other versions
DE69732535T2 (de
Inventor
Frank Bennett
A Vickers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69732535D1 publication Critical patent/DE69732535D1/de
Publication of DE69732535T2 publication Critical patent/DE69732535T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
DE69732535T 1996-12-31 1997-12-16 Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression Expired - Lifetime DE69732535T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US777266 1996-12-31
US08/777,266 US6077833A (en) 1996-12-31 1996-12-31 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
PCT/US1997/023270 WO1998029124A1 (en) 1996-12-31 1997-12-16 Oligonucleotide compositions and methods for the modulation of the expression of b7 protein

Publications (2)

Publication Number Publication Date
DE69732535D1 true DE69732535D1 (de) 2005-03-24
DE69732535T2 DE69732535T2 (de) 2006-03-30

Family

ID=25109768

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69732535T Expired - Lifetime DE69732535T2 (de) 1996-12-31 1997-12-16 Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression

Country Status (10)

Country Link
US (1) US6077833A (de)
EP (1) EP0957926B1 (de)
JP (1) JP3471025B2 (de)
KR (1) KR100452105B1 (de)
AT (1) ATE289200T1 (de)
AU (1) AU720969B2 (de)
CA (1) CA2274581C (de)
DE (1) DE69732535T2 (de)
ES (1) ES2238083T3 (de)
WO (1) WO1998029124A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033977A1 (en) * 1990-08-14 2004-02-19 Bennett C. Frank Oligonucleotide modulation of cell adhesion
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6369209B1 (en) * 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
CA2279669A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acid processing components for therapeutic and diagnostic uses
US7115580B1 (en) * 1996-12-31 2006-10-03 Isis Pharmaceuticals, Inc. Antisense modulation of B7 protein expression
US6319906B1 (en) * 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US20030165888A1 (en) 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
US6518017B1 (en) * 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
KR20020007359A (ko) * 1999-04-08 2002-01-26 추후제출 프라이머 쌍들의 증폭 및 시퀀싱 및 그 이용
EP1085085A1 (de) * 1999-09-18 2001-03-21 Ahmed Dr. Sheriff Verfahren zur Reduzierung von spezifischen Immunreaktionen
WO2000066715A1 (de) * 1999-05-04 2000-11-09 Genethor Gmbh Verfahren zur reduzierung von spezifischen immunreaktionen
DE60044904D1 (de) 1999-09-03 2010-10-14 Brigham & Womens Hospital Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien
JP2003509030A (ja) * 1999-09-17 2003-03-11 アイシス・ファーマシューティカルス・インコーポレーテッド トランスフォーミング成長因子−β発現のアンチセンスオリゴヌクレオチド調節
ES2298269T3 (es) * 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
US20050019915A1 (en) * 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
EP2270024B1 (de) * 2001-06-21 2018-10-24 Ionis Pharmaceuticals, Inc. Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
US20030054354A1 (en) * 2001-08-23 2003-03-20 Bennett C. Frank Use of antisense oligonucleotide libraries for identifying gene function
US20040044404A1 (en) * 2002-08-30 2004-03-04 Stucke Sean M. Retention coatings for delivery systems
US7960355B2 (en) * 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) * 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO2005017163A2 (en) * 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
CN103432079A (zh) * 2004-05-12 2013-12-11 巴克斯特国际公司 含有寡核苷酸的微球体及其在制备用于治疗1型糖尿病的药物中的应用
US7815941B2 (en) * 2004-05-12 2010-10-19 Baxter Healthcare S.A. Nucleic acid microspheres, production and delivery thereof
KR100721928B1 (ko) * 2004-11-05 2007-05-28 주식회사 바이오씨에스 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
CN101500616A (zh) 2006-08-04 2009-08-05 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
MX2009011218A (es) * 2007-04-17 2010-02-11 Baxter Int Microparticulas de acido nucleico para administracion pulmonar.
US8841429B2 (en) 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
US20110172296A1 (en) * 2010-01-12 2011-07-14 Bennett C Frank Modulation of transforming growth factor-beta 1 expression
EP3757214B1 (de) 2014-04-01 2022-06-15 Biogen MA Inc. Zusammensetzungen zur modulierung der sod-1-expression
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5264423A (en) * 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5218105A (en) * 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5242906A (en) * 1991-04-22 1993-09-07 University Of North Carolina At Chapel Hill Antisense oligonucleotides against Epstein-Barr virus
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
DE69333698T2 (de) * 1992-07-20 2005-12-01 Isis Pharmaceutical, Inc., Carlsbad Pseudo-halbknoten ausbildende rna durch hybridisierung von antisenseoligonnukleotiden an gezielte rna sekundärstrukturen
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
EP0600591B1 (de) * 1992-10-02 2003-05-02 Bristol-Myers Squibb Company Hemmung des Tumorzellwachstums durch Verabreichung von B7-transfizierten Zellen
AU7405294A (en) * 1993-07-26 1995-02-20 Dana-Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor
WO1995007358A1 (en) * 1993-07-30 1995-03-16 University Of Medicine & Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
AU7526894A (en) * 1993-08-16 1995-03-14 Arch Development Corporation B7-2: ctla4/cd28 counter receptor
WO1995006738A1 (en) * 1993-09-03 1995-03-09 Schering Corporation B70(b7-2):ctla-4 bonding protein
JPH0779793A (ja) * 1993-09-14 1995-03-28 Sumitomo Electric Ind Ltd Ｂ７０分子に対するモノクローナル抗体
WO1995032734A1 (en) * 1994-05-26 1995-12-07 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness
EP0784482A2 (de) * 1994-06-07 1997-07-23 The Regents Of The University Of Minnesota Methode zur inhibition der antigen spezifischen t-zellen immunantwort
EP0789774A2 (de) * 1994-10-03 1997-08-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Erhöhte immunantwort durch einführen von einem zytokingen und/oder einem kostimulierenden b7-gen in einem rekombinanten virus-exprimierenden system
WO1996015780A1 (en) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection

Also Published As

Publication number Publication date
EP0957926B1 (de) 2005-02-16
ES2238083T3 (es) 2005-08-16
DE69732535T2 (de) 2006-03-30
US6077833A (en) 2000-06-20
JP2000507833A (ja) 2000-06-27
AU5705198A (en) 1998-07-31
ATE289200T1 (de) 2005-03-15
CA2274581A1 (en) 1998-07-09
CA2274581C (en) 2004-02-10
WO1998029124A1 (en) 1998-07-09
KR20000062274A (ko) 2000-10-25
KR100452105B1 (ko) 2004-10-08
EP0957926A1 (de) 1999-11-24
AU720969B2 (en) 2000-06-22
EP0957926A4 (de) 2002-01-23
JP3471025B2 (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
DE69732535D1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
ATE244506T1 (de) Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
DE69729179D1 (de) Kohlenhydratmodifizierte luckenhafte oligonukleotide
DE69233599D1 (de) Unterbrochene 2'-modifizierte Oligonukleotide
DE69824597D1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
DE69535540D1 (de) Zusammensetzung enthaltend nukleinsäuren und kationische polymere, zubereitung und verwendung
EP1131465A4 (de) Antisense-modulierung der interleukin-15 expression
PT1117672E (pt) Modulação anti-sentido da expressão de survivina
CA2296535A1 (en) Antisense oligonucleotide inhibition of ras
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
EP1135402A4 (de) Antisense modulation der egr-1 expression
CA2281895A1 (en) Ikb kinases
DE69826493D1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
ATE245190T1 (de) Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung
EP1131332A4 (de) Antisense-modulation der inhibitor-kappa b kinase-beta expression
ATE291621T1 (de) Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen
DE69929683D1 (de) Antisense modulierung von lfa-3
DE60224778D1 (de) Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen
EP1210454A4 (de) Einflussnahme auf die shp-eprimierung durch antisense
WO2003106647A3 (en) ANTISENSE MODULATION OF JUNCTION ADHESION MOLECULE 3 EXPRESSION
WO2003040320A3 (en) Antisense modulation of human collapsin response mediator protein 2 expression
ATE339498T1 (de) Verändertes protein kinase a-spezifisches hybrid oligonukleotid in kombination mit paclitaxol und verfahren ihrer anwendung
MX9709596A (es) Adn catal ??tico.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition